Factors impeding the discovery of an intervention-based treatment for type 1 diabetes

被引:18
作者
von Herrath, M. G. [1 ,2 ]
Korsgren, O. [3 ]
Atkinson, M. A. [4 ,5 ]
机构
[1] La Jolla Inst Allergy & Immunol, Type Diabet Ctr 1, La Jolla, CA 92037 USA
[2] Novo Nordisk Diabet Res & Dev Ctr, Seattle, WA USA
[3] Univ Hosp, Dept Clin Immunol, Uppsala, Sweden
[4] Univ Florida, Dept Pathol, Gainesville, FL 32611 USA
[5] Univ Florida, Dept Pediat, Gainesville, FL USA
关键词
autoimmune disease; beta cells; immune therapy; insulin; type; 1; diabetes; C-PEPTIDE; T-CELLS; ONSET; INSULIN; PANCREAS; PRESERVATION; PATHOGENESIS; EXPRESSION; MOLECULES; ISLETS;
D O I
10.1111/cei.12656
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Type 1 diabetes (T1D) is one of the most common and severe chronic diseases affecting both children and adults. The aetiology of the disease remains unknown, and thus far no 'true' cure for those affected is available. Indeed, exogenous insulin replacement therapy to manage glucose metabolism to the best degree possible remains the current standard of care. However, despite a recent array of truly impressive improvements designed to enhance disease management (e.g. insulin analogues, continuous glucose monitoring, insulin pumps), it is still difficult for the vast majority of patients to reach recommended target HbA1C levels (< 7.0%). As a result of suboptimal disease management, far too many patients with T1D have an increased risk for disease-associated complications such as nephropathy, neuropathy and retinopathy, as well as hypoglycaemia. New treatment modalities are therefore needed urgently to bring a 'true' cure (disease prevention/disease reversal) to patients with T1D. Here we consider issues that collectively pose a major stumbling block in T1D research with respect to identifying a means to prevent and/or cure the disease. We begin this Perspective by discussing new insights emanating from studies of the pancreas in human T1D; findings which may, at least in part, explain why previous interventions seeking disease prevention/reversal have yielded insufficient benefit. We then turn to suggestions that could optimise the outcome of future clinical trials. Finally, we direct attention to recommendations for the global T1D research community; messages we deem to have the potential to improve our chances of finding the elusive T1D 'cure'.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 31 条
[1]   Blood and Islet Phenotypes Indicate Immunological Heterogeneity in Type 1 Diabetes [J].
Arif, Sefina ;
Leete, Pia ;
Nguyen, Vy ;
Marks, Katherine ;
Nor, Nurhanani Mohamed ;
Estorninho, Megan ;
Kronenberg-Versteeg, Deborah ;
Bingley, Polly J. ;
Todd, John A. ;
Guy, Catherine ;
Dunger, David B. ;
Powrie, Jake ;
Willcox, Abby ;
Foulis, Alan K. ;
Richardson, Sarah J. ;
de Rinaldis, Emanuele ;
Morgan, Noel G. ;
Lorenc, Anna ;
Peakman, Mark .
DIABETES, 2014, 63 (11) :3835-3845
[2]   Losing a Grip on the Notion of β-Cell Specificity for Immune Responses in Type 1 Diabetes: Can We Handle the Truth? [J].
Atkinson, Mark A. .
DIABETES, 2014, 63 (11) :3572-3574
[3]   Anti-CD3 antibodies for type 1 diabetes: beyond expectations [J].
Bach, Jean-Francois .
LANCET, 2011, 378 (9790) :459-460
[4]   The Streetlight Effect in Type 1 Diabetes [J].
Battaglia, Manuela ;
Atkinson, Mark A. .
DIABETES, 2015, 64 (04) :1081-1090
[5]   INSITU CHARACTERIZATION OF AUTOIMMUNE PHENOMENA AND EXPRESSION OF HLA MOLECULES IN THE PANCREAS IN DIABETIC INSULITIS [J].
BOTTAZZO, GF ;
DEAN, BM ;
MCNALLY, JM ;
MACKAY, EH ;
SWIFT, PGF ;
GAMBLE, DR .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (06) :353-360
[6]   Immunosuppressive drugs and the risk of cancer after organ transplantation [J].
Dantal, J ;
Soulillou, JP .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (13) :1371-1373
[7]   Recent US Food and Drug Administration Warnings on Hepatitis B Reactivation With Immune-Suppressing and Anticancer Drugs: Just the Tip of the Iceberg? [J].
Di Bisceglie, Adrian M. ;
Lok, Anna S. ;
Martin, Paul ;
Terrault, Norah ;
Perrillo, Robert P. ;
Hoofnagle, Jay H. .
HEPATOLOGY, 2015, 61 (02) :703-711
[8]   Banting Lecture 2009: An Unfinished Journey: Molecular Pathogenesis to Prevention of Type 1A Diabetes [J].
Eisenbarth, George S. .
DIABETES, 2010, 59 (04) :759-774
[9]   Insulin autoimmunity Immunogenetics/immunopathogenesis of type 1A diabetes [J].
Eisenbarth, GS .
IMMUNOLOGY OF DIABETES II: PATHOGENESIS FROM MOUSE TO MAN, 2003, 1005 :109-118
[10]   ABERRANT EXPRESSION OF CLASS-II MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES BY B-CELLS AND HYPEREXPRESSION OF CLASS-I MAJOR HISTOCOMPATIBILITY COMPLEX-MOLECULES BY INSULIN CONTAINING ISLETS IN TYPE-1 (INSULIN-DEPENDENT) DIABETES-MELLITUS [J].
FOULIS, AK ;
FARQUHARSON, MA ;
HARDMAN, R .
DIABETOLOGIA, 1987, 30 (05) :333-343